Abstract: A method for purifying a desired heterologous polypeptide from microbial fermentation broth or homogenate in which it is produced and solubilized is described. This method involves adding to the broth or homogenate an effective amount of a solution of 6,9-diamino-2-ethoxyacridine lactate (ethacridine lactate) to precipitate host cell impurities under conditions wherein the majority of polypeptide remains soluble, and separating the desired polypeptide from the broth or homogenate. The broth or homogenate containing the ethacridine lactate and polypeptide is also disclosed.
Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.
Abstract: The invention provides methods and compositions for modulating vascularization and angiogenesis, including selective modulation of stages of multi-step vascularization and angiogenesis.
Type:
Grant
Filed:
March 12, 2008
Date of Patent:
August 11, 2009
Assignee:
Genentech, Inc.
Inventors:
Mary E. Gerritsen, Jo-Anne S. Hongo, Constance H. Zlot
Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.
Abstract: The invention provides methods and compositions for modulating vascularization and angiogenesis, including selective modulation of stages of multi-step vascularization and angiogenesis.
Type:
Grant
Filed:
April 14, 2004
Date of Patent:
August 5, 2008
Assignee:
Genentech, Inc.
Inventors:
Mary E. Gerritsen, Jo-Anne S. Hongo, Constance H. Zlot
Abstract: The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents, either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.
Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
Type:
Grant
Filed:
September 3, 2002
Date of Patent:
January 30, 2007
Assignee:
Genentech, Inc.
Inventors:
Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
Type:
Grant
Filed:
November 27, 2000
Date of Patent:
June 13, 2006
Assignee:
Genentech, Inc.
Inventors:
Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
Abstract: A process for purifying an antibody is provided. In this process, a mixture containing the antibody and a contaminant is subjected to low pH hydrophobic interaction chromatography (LPHIC) at low salt concentration. The antibody is eluted from the column in the fraction which does not bind thereto. This process can be preceded and followed by other purification steps.
Type:
Grant
Filed:
January 4, 2001
Date of Patent:
May 2, 2006
Assignee:
Genentech, Inc.
Inventors:
Ernst H. Rinderknecht, Gerardo A. Zapata
Abstract: The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain, a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.
Type:
Grant
Filed:
June 30, 1998
Date of Patent:
February 7, 2006
Assignee:
Genentech, Inc.
Inventors:
Paul J. Godowski, Melanie Rose Mark, Dong-Xiao Zhang
Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
Abstract: The invention concerns composititions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based on the identification of cardiotrophin-1 gene amplified in the genome of tumor cells. Such gene amplification is expected to be associated with the overexpression of the gene product and contribute to tumorigenesis. Accordingly, the cardiotrophin-1 polypeptide encoded by the amplified gene is believed to be a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and may act as a predictor of the prognosis of tumor treatment.
Type:
Grant
Filed:
August 25, 2000
Date of Patent:
October 29, 2002
Assignee:
Genentech, Inc.
Inventors:
David Botstein, Audrey Goddard, David A. Lawrence, Diane Pennica, Margaret Ann Roy, William I. Wood
Abstract: The invention herein provides a method for recovering a polypeptide comprising exposing a composition comprising a polypeptide to a reagent which binds to, or modifies, the polypeptide, wherein the reagent is immobilized on a solid phase; and then passing the composition through a filter bearing a charge which is opposite to the charge of the reagent in the composition, so as to remove leached reagent from the composition.
Type:
Grant
Filed:
June 12, 1998
Date of Patent:
September 19, 2000
Assignee:
Genentech, Inc.
Inventors:
Gregory S. Blank, Daljit S. Narindray, Gerardo A. Zapata
Abstract: Hepatocyte growth factor (HGF) receptor agonists are provided. The HGF receptor agonists include HGF receptor antibodies and fragments thereof. The HGF receptor agonists can be employed to substantially enhance HGF receptor activation. The HGF receptor agonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the HGF receptor agonists are also provided.
Type:
Grant
Filed:
June 27, 1997
Date of Patent:
August 8, 2000
Assignee:
Genentech, Inc.
Inventors:
Kenneth J. Hillan, Ralph H. Schwall, Kelly H. Tabor